$HIMS
MediumHims & Hers Health
DTC Health & GLP-1 / Peptide Platform
Current MC
$2.5B
Target
$4.5B
Investment Thesis
HIMS is a DTC health platform with 36%+ short interest despite NVO partnership, peptide arc expansion, multiple global acquisitions, and improving fundamentals in a friendlier macro climate. The short squeeze thesis is structural — short interest can only be so high before covering creates inherent buying pressure. Long around $28.
Catalysts
- NVO partnership de-risks GLP-1 supply chain
- Peptide arc expansion (Huberman endorsement)
- 36%+ short interest = structural covering pressure
- Multiple international DTC acquisitions expanding distribution
Risks
- GLP-1 regulatory risk — FDA could restrict compounding pharmacies
- High short interest = volatile; can go lower before squeeze
From the Feed (1 signals)
Just putting out there... Would have been +15.02% in 2W equal-weighted return on 30 different stocks. $INTC +29.62%, $MRVL +40.95%, $TSM +4.72%, $COHR +18.9%, $RKLB +26.76%, $DRAM +12.29%, $AVBO +18.32%, $AMZN +9.17%, $ARM +36.6%, $NBIS +15.22%, $GOOGL +6.41%, $AMKR +32.25%, $HOOD +19.14%, $HIMS +42.53%, $SMTC +18.83%, $POWL +9.26%, $MSFT +11.44%...